Lantheus deploys prostate cancer software in U.S.

2021 01 16 00 14 5464 Prostate Cancer 400

Lantheus Medical Imaging parent Lantheus Holdings said its Pylarify AI prostate cancer software is now commercially available in the U.S.

The artificial intelligence (AI) software uses a deep-learning algorithm that has been trained and validated on more than 3,000 images. It allows healthcare professionals and researchers to perform standardized quantitative assessment of prostate-specific membrane antigen (PSMA) PET/CT images.

The FDA-cleared device can be utilized as a secure web cloud application or within the firewall of an institution on a local server. After it is deployed, the application can be integrated into an institution's existing clinical workflow, Lantheus said.

Syntermed is the first U.S. distributor of Pylarify AI.

Page 1 of 435
Next Page